Handbook of Novel Psychoactive Substances
What Clinicians Should Know about NPS
Herausgeber: Corazza, Ornella; Roman-Urrestarazu, Andres
Handbook of Novel Psychoactive Substances
What Clinicians Should Know about NPS
Herausgeber: Corazza, Ornella; Roman-Urrestarazu, Andres
- Broschiertes Buch
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
Handbook of Novel Psychoactive Substances provides an overview of the challenges that clinicians face when dealing with NPS and discusses how the profile of patients and their socio-demographic characteristics frame the serious public health concern that NPS pose.
Andere Kunden interessierten sich auch für
- Posttraumatic Stress and Substance Use Disorders137,99 €
- Anxiety Disorders61,99 €
- Adapting Evidence-Based Eating Disorder Treatments for Novel Populations and Settings56,99 €
- Richard Bryant-JefferiesProblem Drinking42,99 €
- Manufacture of Narcotic Drugs Psychotropic Substances and Their Precursors 200723,99 €
- Edith S GombergCurrent Issues in Alcohol/Drug Studies36,99 €
- Shulamith L A StraussnerNeurobiology of Addictions52,99 €
-
-
-
Handbook of Novel Psychoactive Substances provides an overview of the challenges that clinicians face when dealing with NPS and discusses how the profile of patients and their socio-demographic characteristics frame the serious public health concern that NPS pose.
Produktdetails
- Produktdetails
- Verlag: CRC Press
- Seitenzahl: 386
- Erscheinungstermin: 17. Oktober 2018
- Englisch
- Abmessung: 251mm x 175mm x 23mm
- Gewicht: 757g
- ISBN-13: 9781138068308
- ISBN-10: 1138068306
- Artikelnr.: 54430002
- Verlag: CRC Press
- Seitenzahl: 386
- Erscheinungstermin: 17. Oktober 2018
- Englisch
- Abmessung: 251mm x 175mm x 23mm
- Gewicht: 757g
- ISBN-13: 9781138068308
- ISBN-10: 1138068306
- Artikelnr.: 54430002
Ornella Corazza, MA, PhD, is a Reader in Substance Addictions and Behaviours at the University of Hertfordshire (UK), where she leads a multidisciplinary team across a diverse portfolio in public health and drug policy research. Results of her work have been presented in over a hundred peer-reviewed publications, policy reports and invited lectures internationally. Andres Roman-Urrestarazu, MD, PhD, specializes in the crossover of psychiatry, substance abuse, health economics, and international health policy. He is currently Gillings Fellow in Global Public Health at the University of Cambridge (UK) and assistant professor at Maastricht University (Netherlands). He has held appointments at Trinity Hall, Cambridge and the London School of Economics and Political Science, working extensively on substance misuse and New Psychoactive Substances.
Author biographies Foreword 1. Overcoming the NPS challenge: an
introduction SECTION ONE NPS Users: Prevalence, Patterns, and Prevention 2.
The need for clinical guidelines on NPS: NEPTUNE 3. NPS: epidemiology, user
group characteristics, patterns, motives, and problems 4. The NPS crisis in
British prisons 5. Current trends in performance- and image-enhancing
substance use among gym goers, exercisers, and athletes SECTION TWO
Clinical Recommendations and Best Practices Across Front-Line Health
Professionals 6. NPS in emergency rooms: dealing with aggressiveness and
psychomotor agitation 7. A sentinel and design model of evidence collection
on acute drug and NPS toxicity: the Euro-Den Plus Project 8. Novel and
traditional club substances' association to psychopathological and medical
sequelae: the Ibiza project SECTION THREE Substances, Adverse Effects, and
Clinical Management 9. Spice drugs, synthetic cannabinoids, and
"Spiceophrenia" 10. Synthetic cannabinoids, opioids, and polydrug use:
clinical implications 11. Synthetic cathinones and related fatalities in
the United Kingdom 12. Marvin the Paranoid Android and Alice in Wonderland:
two case reports of synthetic cathinones abuse 13. Clinical aspects related
to methylphenidate-based NPS 14. The worldwide spread of "Herbal Highs":
the case of Kratom 15. Clinical and medical management of conditions caused
by MDMA or "Ecstasy" 16. Clinical effects of 2C-B abuse 17. "In and Out of
the Hole": an exploration on phencyclidine derivatives 18. Fentanyl and
related opioids: new trends, dangers, and management 19. Designer
benzodiazepines: new challenges and treatment options 20. Misuse,
recreational use, and addiction in relation to prescription medicines
introduction SECTION ONE NPS Users: Prevalence, Patterns, and Prevention 2.
The need for clinical guidelines on NPS: NEPTUNE 3. NPS: epidemiology, user
group characteristics, patterns, motives, and problems 4. The NPS crisis in
British prisons 5. Current trends in performance- and image-enhancing
substance use among gym goers, exercisers, and athletes SECTION TWO
Clinical Recommendations and Best Practices Across Front-Line Health
Professionals 6. NPS in emergency rooms: dealing with aggressiveness and
psychomotor agitation 7. A sentinel and design model of evidence collection
on acute drug and NPS toxicity: the Euro-Den Plus Project 8. Novel and
traditional club substances' association to psychopathological and medical
sequelae: the Ibiza project SECTION THREE Substances, Adverse Effects, and
Clinical Management 9. Spice drugs, synthetic cannabinoids, and
"Spiceophrenia" 10. Synthetic cannabinoids, opioids, and polydrug use:
clinical implications 11. Synthetic cathinones and related fatalities in
the United Kingdom 12. Marvin the Paranoid Android and Alice in Wonderland:
two case reports of synthetic cathinones abuse 13. Clinical aspects related
to methylphenidate-based NPS 14. The worldwide spread of "Herbal Highs":
the case of Kratom 15. Clinical and medical management of conditions caused
by MDMA or "Ecstasy" 16. Clinical effects of 2C-B abuse 17. "In and Out of
the Hole": an exploration on phencyclidine derivatives 18. Fentanyl and
related opioids: new trends, dangers, and management 19. Designer
benzodiazepines: new challenges and treatment options 20. Misuse,
recreational use, and addiction in relation to prescription medicines
Author biographies Foreword 1. Overcoming the NPS challenge: an
introduction SECTION ONE NPS Users: Prevalence, Patterns, and Prevention 2.
The need for clinical guidelines on NPS: NEPTUNE 3. NPS: epidemiology, user
group characteristics, patterns, motives, and problems 4. The NPS crisis in
British prisons 5. Current trends in performance- and image-enhancing
substance use among gym goers, exercisers, and athletes SECTION TWO
Clinical Recommendations and Best Practices Across Front-Line Health
Professionals 6. NPS in emergency rooms: dealing with aggressiveness and
psychomotor agitation 7. A sentinel and design model of evidence collection
on acute drug and NPS toxicity: the Euro-Den Plus Project 8. Novel and
traditional club substances' association to psychopathological and medical
sequelae: the Ibiza project SECTION THREE Substances, Adverse Effects, and
Clinical Management 9. Spice drugs, synthetic cannabinoids, and
"Spiceophrenia" 10. Synthetic cannabinoids, opioids, and polydrug use:
clinical implications 11. Synthetic cathinones and related fatalities in
the United Kingdom 12. Marvin the Paranoid Android and Alice in Wonderland:
two case reports of synthetic cathinones abuse 13. Clinical aspects related
to methylphenidate-based NPS 14. The worldwide spread of "Herbal Highs":
the case of Kratom 15. Clinical and medical management of conditions caused
by MDMA or "Ecstasy" 16. Clinical effects of 2C-B abuse 17. "In and Out of
the Hole": an exploration on phencyclidine derivatives 18. Fentanyl and
related opioids: new trends, dangers, and management 19. Designer
benzodiazepines: new challenges and treatment options 20. Misuse,
recreational use, and addiction in relation to prescription medicines
introduction SECTION ONE NPS Users: Prevalence, Patterns, and Prevention 2.
The need for clinical guidelines on NPS: NEPTUNE 3. NPS: epidemiology, user
group characteristics, patterns, motives, and problems 4. The NPS crisis in
British prisons 5. Current trends in performance- and image-enhancing
substance use among gym goers, exercisers, and athletes SECTION TWO
Clinical Recommendations and Best Practices Across Front-Line Health
Professionals 6. NPS in emergency rooms: dealing with aggressiveness and
psychomotor agitation 7. A sentinel and design model of evidence collection
on acute drug and NPS toxicity: the Euro-Den Plus Project 8. Novel and
traditional club substances' association to psychopathological and medical
sequelae: the Ibiza project SECTION THREE Substances, Adverse Effects, and
Clinical Management 9. Spice drugs, synthetic cannabinoids, and
"Spiceophrenia" 10. Synthetic cannabinoids, opioids, and polydrug use:
clinical implications 11. Synthetic cathinones and related fatalities in
the United Kingdom 12. Marvin the Paranoid Android and Alice in Wonderland:
two case reports of synthetic cathinones abuse 13. Clinical aspects related
to methylphenidate-based NPS 14. The worldwide spread of "Herbal Highs":
the case of Kratom 15. Clinical and medical management of conditions caused
by MDMA or "Ecstasy" 16. Clinical effects of 2C-B abuse 17. "In and Out of
the Hole": an exploration on phencyclidine derivatives 18. Fentanyl and
related opioids: new trends, dangers, and management 19. Designer
benzodiazepines: new challenges and treatment options 20. Misuse,
recreational use, and addiction in relation to prescription medicines